BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/25/2014 12:31:00 PM | Browse: 972 | Download: 1166
 |
Received |
|
2014-07-22 08:33 |
|
Peer-Review Started |
|
2014-07-22 15:36 |
|
To Make the First Decision |
|
2014-08-14 15:00 |
|
Return for Revision |
|
2014-08-18 17:19 |
|
Revised |
|
2014-08-27 03:14 |
|
Second Decision |
|
2014-09-01 15:15 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-09-01 15:20 |
|
Articles in Press |
|
2014-09-01 15:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-09-15 12:56 |
|
Publish the Manuscript Online |
|
2014-09-25 12:31 |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Kallikrein-kinin in stem cell therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Julie Chao, Grant Bledsoe and Lee Chao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Institutes of Health |
HL118516 |
| National Institutes of Health |
HL29397 |
| National Institutes of Health |
HL44083 |
|
| Corresponding Author |
Julie Chao, PhD, Professor, Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425, United States. chaoj@musc.edu |
| Key Words |
Tissue kallikrein; Plasma kallikrein; Kinin; Mesenchymal stem cells; Endothelial progenitor cells; Neural stem cells; Heart; Kidney; Brain |
| Core Tip |
Tissue kallikrein-kinin exerts beneficial actions in the cardiovascular, renal and central nervous systems. Recent studies demonstrated that genetic modification of mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) by tissue kallikrein provides enhanced protection against renal ischemia/reperfusion, lupus nephritis, myocardial infarction and hindlimb ischemia. Tissue kallikrein stimulates the proliferation, viability, migration and functional activity of cultured MSCs, EPCs and neural stem cells. Moreover, plasma kallikrein-kinin augments EPC mobility and function in arthritis, whereas the cleaved kininogen product of plasma kallikrein inhibits EPC viability and tube formation. Thus, kallikrein-kinin may enhance the efficacy of stem cell therapy for human diseases. |
| Publish Date |
2014-09-25 12:31 |
| Citation |
Chao J, Bledsoe G, Chao L. Kallikrein-kinin in stem cell therapy. World J Stem Cells 2014; 6(4): 448-457 |
| URL |
http://www.wjgnet.com/1948-0210/full/v6/i4/448.htm |
| DOI |
http://dx.doi.org/10.4252/wjsc.v6.i4.448 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
